Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01765790 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
A Phase 1 study, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT01765790 is a Phase 1 study that has completed, run by Baxalta now part of Shire. The registered enrollment target is 68 participants.
The verdict
NCT01765790, a Phase 1 study, has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-MIF antibody in subjects with malignant solid tumors (Arm 1) and in subjects with metastatic adenocarcinoma of the colon or rectum (Arm 2).
Interventions
- BIOLOGICAL Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2012-06-14 |
| Est. Completion | 2016-07-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01765790
The ClinicalTrials.gov registry entry for NCT01765790 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody is the first listed.
NCT01765790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01765790 about?
NCT01765790 is a clinical study titled "Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors". The purpose of the study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-MIF antibody in subjects with malignant solid tumors (Arm 1) and in subjects with metastatic adenocarcinoma of the colon or rectum (Arm 2).
What is the current status of trial NCT01765790?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2012-06-14. Estimated completion is 2016-07-28.
What interventions are being tested in trial NCT01765790?
The interventions under investigation include: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT01765790?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.